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Objective.Thispilotstudyclinicallytestswhetheraconversionfactorof2to1isappropriatewhenchangingfromoraltoparenteral
morphine administration in the treatment of cancer-related nociceptive pain and calculates the size of an adequately powered
future study. Methods. Eleven outpatients with incurable cancer and well-controlled nociceptive pain were randomly assigned to
either intravenous or subcutaneous morphine using half the previous oral 24-hour dose. Each group crossed over after the ﬁrst
three-day period. Serum concentrations of morphine and its metabolites were monitored as well as intensity of pain. Results.O r a l
to subcutaneous and oral to intravenous quotas of morphine concentrations were approximately 0.9. Subcutaneous to intravenous
morphine quotas were 1. Conclusions. The conversion factor of 2 to 1 seems to be a reasonable average but with an obvious
need for individual adjustments. Concurrent medications and substantially higher doses of morphine could potentially aﬀect the
appropriate conversion factor. An adequately powered study to validate these ﬁndings would need at least 121 patients.
1.Background
In palliative cancer care, morphine is still the strong opioid
of choice according to recommendations by WHO [1]a n d
EAPC[2],anditisrecommendedthatthemorphinebegiven
orallyforaslongaspossible.Diﬃcultiesinswallowingdueto
neurological causes or general weakness during the last days
of life are common reasons for changing the administration
from oral to parenteral. Occasionally, mechanical problems
in the gastrointestinal tract force us to abandon the oral
route of administration early in the disease trajectory. When
expected survival is reasonably long, a switch to transdermal
fentanyl is the least invasive alternative [3]. When death
is imminent, subcutaneous morphine administration is
preferred by many as it provides more ﬂexibility and a lower
possibility of needing to adjust the dose [4]. The clinical task
in these situations is to translate the oral morphine dose to a
parenteral dose in the safest possible way, that is, to maintain
pain control without side eﬀects.
The recommendation used to be a conversion factor
from oral to parenteral morphine of 3 to 1 [5], which has
also been proposed earlier this year by the Cleveland group
[6] .R e c e n t l y ,ac o n v e r s i o nf a c t o rc l o s e rt o2t o1h a sb e e n
recommended [7]. There has also been some discussion as
to whether subcutaneous and intravenous administration
needs diﬀerent dose calculations. These varying recommen-
dations have created a feeling of uncertainty for prescribing
physicians. Our clinical impression is that the factor 2 to 1
works well when changing from stable oral morphine dose
to subcutaneous infusion. Complications such as episodes of
breakthrough pain and/or signs of overdosing are rare.
This study investigates the use of a conversion factor of
2 to1 in clinical practice, to evaluate pain control and side
eﬀects systematically and to monitor eﬀects on plasma con-
centrations of morphine, morphine-3-glucoronide (M3G),
and morphine-6-glucoronide (M6G). A secondary aim was
to examine whether any diﬀerences could be detected in
plasma concentrations of morphine and its metabolites2 Pain Research and Treatment
comparing subcutaneous and intravenous infusion. The
hypothesis was that quotas between morphine plasma con-
centrations after oral administration and subcutaneous or
intravenous administration would be approximately 1. A
furtheraimwastousetheresultsofthisstudytocalculatethe
needed number of patients in a future adequately powered
study.
2. Methods
2.1. Patients. Eleven incurable cancer patients treated at
home by the palliative care team in ¨ Ostersund, Sweden were
approached. All were receiving ongoing controlled release
morphine therapy (Dolcontin, Pﬁzer), and their cancer-
related pain was well controlled (Numerical Rating Scale
(NRS) < 4). We deliberately looked for patients who had
a survival prognosis of more than one month and whose
cognition was intact. All patients received information about
the study and gave informed consent in writing. Ethical
approval was given by the Ethical Committee of Ume˚ a
University.
2.2. Procedure. Blood samples were taken within one hour
before the regular morning dose of oral morphine. Plasma
concentrations of morphine, M3G, and M6G were analyzed
by high-performance liquid chromatography (HPLC) at
Huddinge University Hospital. Blood for analysis of creati-
nine and liver tests were performed.
New plasma concentrations were taken four to ﬁve
hours after the regular morning dose of oral-controlled
release morphine. Patients were then randomly assigned
to groups and given either subcutaneous or intravenous
continuous infusion of morphine. We used a seven-day
INFUSOR produced by Baxter, which delivered 0.5ml/hour
of a mixture equaling half the previous oral dose per 24
hours. Three days later, the groups switched to the other
way of parenteral administration using the same 24-hour
morphine dose. Plasma concentrations were taken before
the switch and again after at least 48 hours of the new
mode of administration. Demographical and clinical data
were recorded in a study protocol. The Eastern Cooperative
Oncology Group Scale of Performance Status (ECOG PS)
was used to assess patients’ functional status [8]. Body Mass
Index (BMI) was calculated, and Numerical Rating Scale
(NRS) measurements of pain, nausea, and tiredness were
undertaken daily throughout the weeklong study period.
An increase in NRS score of >1 was regarded as clinically
signiﬁcant.
2.3. Statistics. Statistical comparisons of NRS ratings taken
during the diﬀerent ways of administration were performed
using nonparametric the Wilcoxon signed rank test. Mann-
Whitney U analysis was used when comparing metabo-
lite concentrations between those who experienced more
pain during parenteral administration with those without
increased pain ratings.
P o w e rc a l c u l a t i o n sw e r ep e r f o r m e dt os e eh o wm a n y
patients that would be needed to conclude that a conversion
factorof2isappropriate.Anequivalencetestwasdesignedin
which equivalence of the conversion factor was deﬁned as an
interval 2+/−d. Thus, the null hypothesis (nonequivalence)
was rejected if there were evidence that the true conversion
factor was inside this interval. The log-transformed quota
between oral and intravenous concentrations was assumed
to be normally distributed with the estimated standard
deviation (SD) as a known parameter.
3. Results
No patient withdrew from the study during the seven-day
study period. The study group of 11 patients consisted of ﬁve
men and six women. Median age was 71 years (range 58–80).
Diagnoses were lung cancer (n = 3), prostate cancer (n = 3),
gynecological cancer (n = 2), GI cancer (n = 2), and breast
cancer (n = 1). Median oral morphine dose was 40mg/24h
(10–200mg/24h). Median survival after study completion
w a s8 0d a y s( I n t e r q u a r t i l eR a n g e ,I Q R= 138).
We divided the oral ﬁve-hour morphine plasma concen-
tration with the intravenous or the subcutaneous morphine
concentration of the same patient forming two quotas.
The median oral to subcutaneous quota for plasma mor-
phine was 0.91 (IQR = 0.39). The median oral to intravenous
quota was 0.88 (IQR = 0.39), and the subcutaneous to
intravenous quota was 1.0 (IQR = 0.29). The distributions
of quotas for the eleven study patients are shown in Figure 1.
The concentrations of morphine-3-glucoronide (=M3G)
and morphine-6-glucoronide (=M6G) were consistently
approximately 2.5 times higher after oral administration
than after parenteral. The median concentration of M3G
divided with M6G was approximately ﬁve (4.7–5.0; IQR 0.8–
1.1) irrespective of route of administration. Median quota of
M3G concentration to morphine concentration was 44 (IQR
= 60), and the median quota of M6G:morphine was 10 (IQR
= 12) at oral administration (Figure 2).
We measured the symptoms occurring during each
administrativemethodandcomparedthemeasurements.We
found that the pain levels increased in ﬁve patients during
parenteral morphine administration (sc P = .04, iv P =
.08). The patients who experienced increased pain during
parenteral administration (median 2 steps on the 0–10 NRS
scale) did not diﬀer in any signiﬁcant way regarding patient
characteristics (age, gender, diagnosis, ECOG, survival, mor-
phinedose,morphine+M6Gconcentration,BMI,livertests,
and creatinine) compared with those with stable pain ratings
(n = 6; Table 1). No increased tiredness could be detected in
parenteraladministration,buttheyexperiencedmorenausea
during intravenous administration (P = .04) compared with
oral.
The only signiﬁcant diﬀerences detected between
patients experiencing more pain compared with those with
maintained pain control were the quotas between oral and
subcutaneous M6G concentrations (P = .04) and oral and
intravenous M6G concentrations (P = .01; Table 2). Both
M6Goral/scandM6Goral/ivquotasweresigniﬁcantlylower
for those patients experiencing more pain with parenteral
administration. It appears that this diﬀerence in quotas was
mostly due to a higher M6G concentration when takingPain Research and Treatment 3
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Figure 1: Quotas of oral morphine concentration and subcu-
taneous morphine: MO/MS, oral morphine concentration and
intravenous morphine: MO/MI (n = 11).
Table 1: Clinical data (n = 11).
Median IQR Normal range
Bilirubin 6.0µmol/L 2.5 3–21
Creatinine 87µmol/L 50 55–115
ALAT 0.32µkat/L 0.63 0.00–0.80
ASAT 0.31µkat/L 0.11 0.00–0.80
BMI∗ 23 7
ECOG∗∗ 21
∗BMI: Body Mass Index.
∗∗ECOG:(1)abletocarryoutlightwork,(2)upandabout>50%ofwaking
hours, (3) conﬁned to bed or chair >50% of waking hours.
morphine orally in patients not experiencing increased pain
when changing to parenteral administration.
The SD for the log-transformed quota between oral and
intravenous concentrations was estimated at 0.38 for the
11 patients. The number of patients needed to reach the
power of 60% was 56, and for 80% it was 78 using the
equivalencedeﬁnition2+/−0.25.Thecorrespondingnumber
using equivalence 2+/−0.2 was 87 and 121, respectively.
4. Discussion
This study shows that morphine concentrations are approx-
imately the same—quotas (oral/sc or oral/iv) of 0.88–0.91—
if using a conversion factor of 2 to 1, when changing from
oral to parenteral administration of morphine. In spite
of slightly higher morphine concentrations with parenteral
administration, ﬁve out of 11 patients experienced more
pain. This provokes two thoughts: this suggests that pain
m i g h th a v eb e e ne v e nm o r eo fap r o b l e mi fw eh a dc h o s e n
a conversion factor of 3 to 1; that is, we had chosen an
even lower parenteral morphine dose, and this conﬁrms that
morphine concentrations alone cannot be used to predict
analgesic eﬀects [9, 10].
The interindividual variation of these quotas was rather
substantial (from 0.59 to 1.96). This means in practice that,
even though the median patient received the same morphine
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Figure 2: Quotas of oral morphine-3-glucoronide and morphine
concentration: M3O/MO and oral morphine-6-glucoronide and
morphine concentration: M6O/MO (n = 11).
Table 2: M6G concentrations and quotas in patients experiencing
more pain (yes) in parenteral administration than in oral compared
with those with maintained pain control (no).
Yes (n = 5)
Median (IQR) No (n = 6) P value
median (IQR)
Oral M6G: iv M6G 1.9 (0.28) 2.7 (0.80) .01
Oral M6G: sc M6G 2.2 (0.85) 3.1 (0.71) .04
Oral M6G 225nmol/L
(908) 538 (464)
Iv M6G 120 (544) 168 (186)
Sc M6G 120 (775) 178 (178)
concentrations with this conversion factor, those in the
outer ranges might be given anything from double to half
the morphine concentration when it is given parenterally
compared with when it is given orally.
In this study, no harmful eﬀects correlated to varying
morphine concentrations after conversion to parenteral
administration could be detected. It still underlines the
importance of individual dose titration and the need for
an individual evaluation of every patient after a switch has
beenmadefromoraltoparenteralmorphineadministration.
The identical concentrations of morphine noted in both
subcutaneous and intravenous administration support the
use of the same conversion factor for both [11]. The
ﬁndingofidenticalproportionsofmetaboliteconcentrations
irrespective of which way of parenteral administration was
used further strengthens the same conclusion.
The substantial drop in metabolite concentrations with
parenteral administration (median = 2.5 to 1) could be
worth remembering in a clinical situation, where side
eﬀects because high M3G levels are suspected as a change
from oral morphine to parenteral may ease the symptoms.
The lower metabolite levels (especially M6G) in parenteral
administration may also partly explain the higher pain levels
experienced by some patients. As we did not identify any
clear-cut diﬀerences between those with increased pain and
those with continued good pain control except in oral to4 Pain Research and Treatment
parenteral M6G quotas, it is perhaps unsafe to draw any ﬁrm
conclusion beyond saying that this does not contradict the
assumption that M6G contributes somewhat to the analgesic
eﬀects of morphine [12]. As our study captured merely a
week in the lives of our patients whose median survival
after study was almost three months, disease progression
does not seem to be the most likely explanation of the pain
increase. Nevertheless, incurable cancer patients admitted to
a palliative homecare team are bound to be suﬀering from a
relativelysymptomintensivedisease,asituationthatrequires
us to consider the confounding eﬀect that this may have had
on pain levels during the study.
The limited number of participating patients deﬁnitely
disqualiﬁes us from making any conclusions regarding
concentrations or quotas explaining diﬀerent symptomatic
eﬀects. If mass signiﬁcance can be ruled out, the ﬁnding of
M6G quotas being involved in pain response may, at the
most, be regarded as a ﬁnding generating new hypotheses.
The calculated quotas of morphine and its metabolites are
within the same range as those reported elsewhere [5, 9, 13,
14]. Admittedly, this is not an exact science, especially as the
day-to-day variations of registered plasma concentrations in
constant doses of oral morphine may vary as much as 18%
to 46% [15].
This study included cancer patients with continuous
morphine therapy. Each studied way of administration was
used for at least 48 hours before blood samples were taken.
Thus, measured blood concentrations illustrate steady state,
as the time limit of ﬁve times the halﬂife of morphine (2
to 4 hours) was well exceeded. Nevertheless, this study does
not cover morphine doses higher than low to moderate.
Concurrent medications interacting with the metabolism
and excretion of morphine may also aﬀect the proposed
conversion factor.
To perform an adequately powered study with the same
methodology, 121 patients need to be included if we want
80% power and an acceptable range of the conversion factor
to be 2+/−0.2. To manage such an eﬀo r t ,am u l t i c e n t r e
approach would be the only design with a reasonable chance
of success.
5. Conclusion
This pilot study clinically tests the feasibility of a conversion
factor of 2 to 1 when changing from oral to parenteral
morphine and supports this with concentration measure-
ments of morphine and its metabolites. We did not ﬁnd
any substantial evidence contradicting the advice that a
conversion factor of 2 to 1 works rather well in clinical
practice. As we found a tendency of less analgesic eﬀect, our
conclusion is that the conversion factor deﬁnitely should be
2 to 1 as recommended by Takahashi et al. [7] rather than
3 to 1. It is clear that this conversion factor should be used
sensitively, and individual monitoring of analgesic eﬀects
and side eﬀects are of utmost importance after changing
the way morphine is administered. Concurrent medications
interacting with morphine metabolism and doses exceeding
those examined in this study may necessitate dose titration
with some patients. To validate the ﬁndings in this pilot
study, an adequately powered study would need at least 121
patients.
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